跳至主要内容
临床试验/NCT05366530
NCT05366530
终止
不适用

IdeNtification of SPecific EleCTrophenotypes in Atrial Fibrillation

Imperial College London1 个研究点 分布在 1 个国家目标入组 1 人2022年5月19日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Atrial Fibrillation
发起方
Imperial College London
入组人数
1
试验地点
1
主要终点
Freedom From Atrial Fibrillation
状态
终止
最后更新
上个月

概览

简要总结

This study will investigate a common heart rhythm disturbance (arrhythmia), atrial fibrillation (AF), to improve understanding of how best to treat it in different patients. Direct current cardioversion (DCCV) is a procedure that can revert the heart to a normal rhythm, however almost all patients will only have a transient benefit, and their heart will return to the abnormal rhythm, AF. Ablation is an invasive procedure that creates scar tissue within the heart to reduce the arrhythmias, with a longer lasting effect than DCCV. It has been used with success in AF that occurs occasionally (paroxysmal) but is not as effective in AF that is more long-lasting, also known as persistent AF. Persistent AF is major cause of symptoms of breathlessness and palpitations and significantly increases the risk of stroke. Doctors are unable to accurately predict which patients will benefit most from an ablation, this can lead to as many as 50% of patients not benefitting from the procedure. The aim is to better predict which patients will benefit from an ablation. The study will include patients undergoing AF ablation or DCCV and perform additional tests including blood tests a heart MRI scan, a special type of heart tracing with up to 252 points and a short period of extra recordings from within the heart during the ablation procedure. Several techniques will be used to analyse this data, including machine learning, to develop a means predict which patients will benefit the most from the ablation procedure, without needing to use any recordings from within the heart.

注册库
clinicaltrials.gov
开始日期
2022年5月19日
结束日期
2024年8月27日
最后更新
上个月
研究类型
Observational
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Suitable candidate for catheter mapping/ablation for arrhythmias or direct current cardioversion for atrial fibrillation
  • Signed Informed Consent

排除标准

  • Severe cerebrovascular disease
  • Moderate to severe renal impairment (eGFR \< 30)
  • Active gastrointestinal bleeding
  • Active infection or fever
  • Short life expectancy
  • Significant anaemia
  • Severe uncontrolled systemic hypertension
  • Severe electrolyte imbalance
  • Congestive heart failure - NYHA Class IV
  • Recent myocardial infarction

结局指标

主要结局

Freedom From Atrial Fibrillation

时间窗: 1 year

Percentage of patients who do not have a recurrence of atrial fibrillation

研究点 (1)

Loading locations...

相似试验